🚀 VC round data is live in beta, check it out!
Gedeon Richter Valuation Multiples
Discover revenue and EBITDA valuation multiples for Gedeon Richter and similar public comparables like PharmaEssentia, Samchundang Pharm, ImmunityBio, 3SBio and more.
Gedeon Richter Overview
About Gedeon Richter
Chemical Works of Gedeon Richter PLC is a pharmaceutical company. The company focuses on the development and manufacture of gynaecological, cardiovascular, and central nervous system products. It manufactures medicines including original, generic and licensed products for treatment in the therapeutic area. The group is active in two business segments namely, the Pharma segment comprising Women’s Healthcare, Neuropsychiatry, Biotechnology, General Medicine, and Other pharma; and the Others segment includes the remaining wholesale and retail business of the Group and all other activities. The company operates internationally.
Founded
1923
HQ
Employees
11.6K
Website
Sectors
Financials (LTM)
EV
$7B
Gedeon Richter Financials
Gedeon Richter reported last 12-month revenue of $3B and EBITDA of $1B.
In the same LTM period, Gedeon Richter generated $2B in gross profit, $1B in EBITDA, and $767M in net income.
Revenue (LTM)
Gedeon Richter P&L
In the most recent fiscal year, Gedeon Richter reported revenue of $3B and EBITDA of $1B.
Gedeon Richter expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 69% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $1B | XXX | $1B | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 40% | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | 32% | XXX | XXX | XXX |
| Net Profit | $767M | XXX | $774M | XXX | XXX | XXX |
| Net Margin | 26% | XXX | 28% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Gedeon Richter Stock Performance
Gedeon Richter has current market cap of $8B, and enterprise value of $7B.
Market Cap Evolution
Gedeon Richter's stock price is $42.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7B | $8B | 2.5% | XXX | XXX | XXX | $4.23 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialGedeon Richter Valuation Multiples
Gedeon Richter trades at 2.5x EV/Revenue multiple, and 6.5x EV/EBITDA.
EV / Revenue (LTM)
Gedeon Richter Financial Valuation Multiples
As of April 18, 2026, Gedeon Richter has market cap of $8B and EV of $7B.
Equity research analysts estimate Gedeon Richter's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Gedeon Richter has a P/E ratio of 10.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.7x | XXX | XXX | XXX |
| EV/EBITDA | 6.5x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBIT | 7.8x | XXX | 8.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | 10.1x | XXX | 10.1x | XXX | XXX | XXX |
| EV/FCF | 11.8x | XXX | 10.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Gedeon Richter Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Gedeon Richter Margins & Growth Rates
Gedeon Richter's revenue in the last 12 month grew by 10%.
Gedeon Richter's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Gedeon Richter's rule of 40 is 48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Gedeon Richter's rule of X is 63% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Gedeon Richter Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | 40% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | (0%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 48% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | 19% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | 7% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Gedeon Richter Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Gedeon Richter | XXX | XXX | XXX | XXX | XXX | XXX |
| PharmaEssentia | XXX | XXX | XXX | XXX | XXX | XXX |
| Samchundang Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| ImmunityBio | XXX | XXX | XXX | XXX | XXX | XXX |
| 3SBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Krystal Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gedeon Richter M&A Activity
Gedeon Richter acquired XXX companies to date.
Last acquisition by Gedeon Richter was on XXXXXXXX, XXXXX. Gedeon Richter acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Gedeon Richter
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialGedeon Richter Investment Activity
Gedeon Richter invested in XXX companies to date.
Gedeon Richter made its latest investment on XXXXXXXX, XXXXX. Gedeon Richter invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Gedeon Richter
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Gedeon Richter
| When was Gedeon Richter founded? | Gedeon Richter was founded in 1923. |
| Where is Gedeon Richter headquartered? | Gedeon Richter is headquartered in Hungary. |
| How many employees does Gedeon Richter have? | As of today, Gedeon Richter has over 11K employees. |
| Is Gedeon Richter publicly listed? | Yes, Gedeon Richter is a public company listed on Budapest Stock Exchange. |
| What is the stock symbol of Gedeon Richter? | Gedeon Richter trades under RICHTER ticker. |
| When did Gedeon Richter go public? | Gedeon Richter went public in 1994. |
| Who are competitors of Gedeon Richter? | Gedeon Richter main competitors are PharmaEssentia, Samchundang Pharm, ImmunityBio, 3SBio. |
| What is the current market cap of Gedeon Richter? | Gedeon Richter's current market cap is $8B. |
| What is the current revenue of Gedeon Richter? | Gedeon Richter's last 12 months revenue is $3B. |
| What is the current revenue growth of Gedeon Richter? | Gedeon Richter revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Gedeon Richter? | Current revenue multiple of Gedeon Richter is 2.5x. |
| Is Gedeon Richter profitable? | Yes, Gedeon Richter is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Gedeon Richter? | Gedeon Richter's last 12 months EBITDA is $1B. |
| What is Gedeon Richter's EBITDA margin? | Gedeon Richter's last 12 months EBITDA margin is 38%. |
| What is the current EV/EBITDA multiple of Gedeon Richter? | Current EBITDA multiple of Gedeon Richter is 6.5x. |
| What is the current FCF of Gedeon Richter? | Gedeon Richter's last 12 months FCF is $625M. |
| What is Gedeon Richter's FCF margin? | Gedeon Richter's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Gedeon Richter? | Current FCF multiple of Gedeon Richter is 11.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.